Citigroup Maintains Buy on Acceleron Pharma, Raises Price Target to $75

Citigroup maintains Acceleron Pharma (NASDAQ:XLRN) with a Buy and raises the price target from $52 to $75.

Benzinga · 01/22/2020 13:12

Citigroup maintains Acceleron Pharma (NASDAQ:XLRN) with a Buy and raises the price target from $52 to $75.